1 which found that gentamicin pharmacokinetics are altered in patients receiving high-frequency oscillatory ventilation (HFOV). However, our enthusiasm was dampened by several concerns. Firstly, we were surprised by the failure of the authors to include any data to support their contention that altered vascular volume did not contribute to the altered pharmacokinetics observed in their study. In reading their article and the data presented, 1 we would tend to agree that the patients who received HFOV would indeed be more critically ill than patients receiving conventional mechanical ventilation (CMV). As postnatal age at time of treatment was significantly greater in the HFOV group (11.7±11 vs 4.63±4.6 hours, p<0.001) than the CMV group and maintenance of adequate intravascular volume is critical for patients treated with HFOV, we speculate that the HFOV group might have received far greater fluid intake (L /kg/day) than the CMV group. The HFOV group is also more likely to have received more fluid boluses for blood pressure support, if, as reported, many of them needed ''high-dose pressors''. As gentamicin is a water-soluble drug whose volume of distribution is dramatically altered by increases in extracellular fluid volume, the substantially greater V d of the HFOV patients might merely be a reflection of their substantially greater extracellular fluid status. While the authors comment ''fluid overload does not appear to be a consistent problem in infants who receive HFOV'', they do not provide any data to clarify whether this is a generic statement or a reference to the patients reported on. Given that they have access to the medical records and input/ output data, it would be seemingly easy and imminently useful to clarify this issue. At the very least, a comparison of the change (if any) in infants' weights during the study period rather than a comparison of birthweights would be more relevant and useful. While clarifying this point will not preclude other pathophysiological mechanisms being responsible, it would support the fact that concomitant fluid therapy rather than ventilator therapy might be responsible for the differences in the two groups. Indeed, increases in extracellular fluid contributing to greater V d of gentamicin (than the 0.49±0.09 l/kg of the CMV group) have previously been reported by the author 2 and others 3, 4 in other critically ill infants treated with extracorporeal membrane oxygenation. Next, the authors' comments regarding prolonged K el and greater T 1/2 in the HFOV group (p<0.002 and <0.007, respectively, when compared with the CMV group) being possibly due to a reduction in glomerular filtration rate (GFR) are contradictory to their subsequent comments regarding the ''increase in clearance of gentamicin results from an increase in GFR''. As
2 a substantial increase in V d will result in a decrease in K el if TBC remains unchanged or minimally increased. The apparent contradictory results (of increased clearance and lower K el ) may be reconciled if one remembers that clearance refers to removal of drug from a volume of plasma in a given unit of time, while K el refers to the fraction of the remaining drug removed per unit time. Given that the V d of the HFOV group is substantially greater than that of the CMV group, it should be no surprise that the fraction of the drug removed per unit time is less in the HFOV group even though the clearance is slightly increased. Hence, the slower elimination rate constant and prolonged T 1/2 more likely reflect the (greater) V d of the HFOV group than a change (decrease) in renal function. As such, the authors' results do not support their premise that HFOV causes a decrease in cardiac output, leading to a decrease in GFR, and reduced elimination of gentamicin.
Lastly, given the results presented in the article, we fail to understand the authors' recommendation to initiate therapy at 2.5 mg/kg every 18 hours. Based on their reported V d of 0.98±0.46 l/kg and K el of 0.081 þ 0.02/hour of patients in the HFOV group, the above regimen would result in serum peaks being substantially below 5 mg/l, which, for a population of extremely sick neonates, is decidedly unacceptable as the therapeutic efficacy of gentamicin is correlated to its peak concentration. 5 Given their results, a more appropriate recommendation for patients treated with HFOV might have been initiating therapy with 4 to 5 mg/kg/ dose every 24 hours as recommended by some, 6, 7 and measuring both peak and trough levels after the first dose to arrive at optimal individualized dosing. An alternative and possibly better approach might be the use of a 5 to 7 mg/kg loading dose followed by once-daily dosing,Dear Editor: The data presented by Drs. Bhatt-Mehta and Donn have added to our knowledge of gentamicin pharmacokinetics in neonates undergoing high-frequency ventilation. Their recommended dosage of 2.5 mg/kg every 18 hours is suspect, however, and cannot be validated since peak and trough concentrations were not reported. The most significant finding in their report was the doubling of the volume of distribution (V d ). A doubling of the V d will decrease the peak concentration by approximately one half. The reported V d of 0.98 l/kg in the HFOV group predicts peak concentrations of approximately 2.5 mg/ml, which are significantly subtherapeutic. A more appropriate recommendation would be to increase the dose to at least 5 mg/kg. The reported serum half-life of 9.23 hours in the HFOV group predicts that a dosing interval of 36 hours (B four half-lives) would be more appropriate. We would like to thank Fernandes and his colleagues for their insight and thoughtful comments on our manuscript. 1 We appreciate the authors' critical analysis of our results. We were also somewhat puzzled by our own results as the authors and have discussed the results of our study primarily in light of our clinical experience keeping the limitations of the retrospective nature of the data in mind and providing minimal speculative arguments. We did not include the comparative data on weight increase in the conventional mechanical ventilation (CMV) and highfrequency oscillatory ventilation (HFOV) groups since the increased volume of distribution in the HFOV group has the same meaning. The average weight gain in the HFOV group was almost twice that of the CMV group; however, when individual patient data were examined in this group this did not appear to be the case. This fact indicates the variability in patient response. The expression of calculated V d expressed as mean±SD may also be somewhat misleading due to small sample size. The authors' explanation of the fluid overload may be valid but for some of our patients only.
THOMAS E. YOUNG, MD
Comparison of this study to our other work [2] [3] [4] is not possible as the clinical situations are very different (extracorporeal membrane oxygenation vs HFOV).
Our comment regarding the compensatory increase in GFR is purely speculative. There may be other pathophysiologic mechanisms responsible for the increase, which are not dependent on cardiac output. While the increased total body clearance (TBC) may be explained based on the somewhat simplified relationship of V d ¼ TBC/K el , in reality the prolonged half-life we observed in the HFOV population would indicate reduced clearance. Certainly, gentamicin-induced nephro-and oto-toxicity is due to persistent high trough concentrations, which should be avoided. Next, while we did not focus on peak plasma concentrations of gentamicin in our report, our data indicate peak concentrations of the antibiotic in the 5 to 9 mg/ml range at steady state for
